Clinomics Inc
Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company's liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (… Read more
Market Cap & Net Worth: Clinomics Inc (352770)
Clinomics Inc (KQ:352770) has a market capitalization of $612.99K (₩897.55 Million) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #37845 globally and #2167 in its home market, demonstrating a -36.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clinomics Inc's stock price ₩350.00 by its total outstanding shares 2564420 (2.56 Million).
Clinomics Inc Market Cap History: 2020 to 2025
Clinomics Inc's market capitalization history from 2020 to 2025. Data shows change from $16.61 Million to $612.99K (-54.28% CAGR).
Index Memberships
Clinomics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.00% | #1184 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.00% | #1184 of 1384 |
Weight: Clinomics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Clinomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clinomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Clinomics Inc's market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $16.61 Million | $9.82 Billion | -$13.15 Billion | 0.00x | N/A |
| 2021 | $12.40 Million | $55.43 Billion | $15.85 Billion | 0.00x | 0.00x |
| 2022 | $6.34 Million | $23.08 Billion | -$10.18 Billion | 0.00x | N/A |
| 2023 | $4.49 Million | $11.41 Billion | -$42.26 Billion | 0.00x | N/A |
| 2024 | $910.73K | $8.50 Billion | -$46.92 Billion | 0.00x | N/A |
Competitor Companies of 352770 by Market Capitalization
Companies near Clinomics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Clinomics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Clinomics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Clinomics Inc's market cap moved from $16.61 Million to $ 612.99K, with a yearly change of -54.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩612.99K | -32.69% |
| 2024 | ₩910.73K | -79.73% |
| 2023 | ₩4.49 Million | -29.13% |
| 2022 | ₩6.34 Million | -48.88% |
| 2021 | ₩12.40 Million | -25.36% |
| 2020 | ₩16.61 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Clinomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $612.99K USD |
| MoneyControl | $612.99K USD |
| MarketWatch | $612.99K USD |
| marketcap.company | $612.99K USD |
| Reuters | $612.99K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.